TCR affinity for p/MHC formed by tumor antigens that are self-proteins: Impact on efficacy and toxicity

Current Opinion in Immunology

Volumn 33, Issue , 2015, Pages 16-22

  Stone, Jennifer D ^a   Harris, Daniel T ^a   Kranz, David M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; HISTOCOMPATIBILITY ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN BINDING;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; CROSS REACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; NONHUMAN; PROTEIN ANALYSIS; RECEPTOR AFFINITY; SAFETY; T LYMPHOCYTE ACTIVATION; ADVERSE EFFECTS; ANIMAL; CHEMISTRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS; PROCEDURES; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, NEOPLASM; CROSS REACTIONS; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTE SUBSETS;

EID: 84921479955     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.01.003     Document Type: Review

References (59)

1. Cheever M.A., Allison J.P., Ferris A.S., Finn O.J., Hastings B.M., Hecht T.T., Mellman I., Prindiville S.A., Viner J.L., Weiner L.M., et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009, 15:5323-5337.
2. Jameson S.C., Hogquist K.A., Bevan M.J. Positive selection of thymocytes. Annu Rev Immunol 1995, 13:93-126.
3. Vrisekoop N., Monteiro J.P., Mandl J.N., Germain R.N. Revisiting thymic positive selection and the mature T cell repertoire for antigen. Immunity 2014, 41:181-190.
4. Kosmrlj A., Read E.L., Qi Y., Allen T.M., Altfeld M., Deeks S.G., Pereyra F., Carrington M., Walker B.D., Chakraborty A.K. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 2010, 465:350-354.
5. Walker B.D., Yu X.G. Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol 2013, 13:487-498.
6. Aleksic M., Liddy N., Molloy P.E., Pumphrey N., Vuidepot A., Chang K.M., Jakobsen B.K. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol 2012, 42:3174-3179.
7. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
8. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., Kammula U.S., Royal R.E., Sherry R.M., Wunderlich J.R., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
9. Stone J.D., Kranz D.M. Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front Immunol 2013, 4:244.
10. Perez-Diez A., Joncker N.T., Choi K., Chan W.F., Anderson C.C., Lantz O., Matzinger P. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007, 109:5346-5354.
11. Soto C.M., Stone J.D., Chervin A.S., Engels B., Schreiber H., Roy E.J., Kranz D.M. MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunol Immunother 2013, 62:359-369.
12. Chervin A.S., Stone J.D., Bowerman N.A., Kranz D.M. Cutting edge: inhibitory effects of CD4 and CD8 on T cell activation induced by high-affinity noncognate ligands. J Immunol 2009, 183:7639-7643.
13. Chervin A.S., Stone J.D., Holler P.D., Bai A., Chen J., Eisen H.N., Kranz D.M. The impact of TCR-binding properties and antigen presentation format on T cell responsiveness. J Immunol 2009, 183:1166-1178.
14. Robbins P.F., Li Y.F., El-Gamil M., Zhao Y., Wargo J.A., Zheng Z., Xu H., Morgan R.A., Feldman S.A., Johnson L.A., et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 2008, 180:6116-6131.
15. Zhao Y., Bennett A.D., Zheng Z., Wang Q.J., Robbins P.F., Yu L.Y., Li Y., Molloy P.E., Dunn S.M., Jakobsen B.K., et al. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol 2007, 179:5845-5854.
16. Holler P.D., Chlewicki L.K., Kranz D.M. TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol 2003, 4:55-62.
17. Engels B., Chervin A.S., Sant A.J., Kranz D.M., Schreiber H. Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity. Mol Ther 2012, 20:652-660.
18. Frankel T.L., Burns W.R., Peng P.D., Yu Z., Chinnasamy D., Wargo J.A., Zheng Z., Restifo N.P., Rosenberg S.A., Morgan R.A. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol 2010, 184:5988-5998.
19. Stone J.D., Harris D.T., Soto C.M., Chervin A.S., Aggen D.H., Roy E.J., Kranz D.M. A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. Cancer Immunol Immunother 2014, 63:1163-1176.
20. Robbins P.F., Morgan R.A., Feldman S.A., Yang J.C., Sherry R.M., Dudley M.E., Wunderlich J.R., Nahvi A.V., Helman L.J., Mackall C.L., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011, 29:917-924.
21. Chinnasamy N., Wargo J.A., Yu Z., Rao M., Frankel T.L., Riley J.P., Hong J.J., Parkhurst M.R., Feldman S.A., Schrump D.S., et al. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol 2011, 186:685-696.
22. Linette G.P., Stadtmauer E.A., Maus M.V., Rapoport A.P., Levine B.L., Emery L., Litzky L., Bagg A., Carreno B.M., Cimino P.J., et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013, 122:863-871.
23. de Witte M.A., Coccoris M., Wolkers M.C., van den Boom M.D., Mesman E.M., Song J.Y., van der Valk M., Haanen J.B., Schumacher T.N. Targeting self-antigens through allogeneic TCR gene transfer. Blood 2006, 108:870-877.
24. Theobald M., Biggs J., Dittmer D., Levine A.J., Sherman L.A. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A 1995, 92:11993-11997.
25. Richman S.A., Kranz D.M. Display, engineering, and applications of antigen-specific T cell receptors. Biomol Eng 2007, 24:361-373.
26. Stone J.D., Chervin A.S., Aggen D.H., Kranz D.M. T cell receptor engineering. Methods Enzymol 2012, 503:189-222.
27. Ashfield R., Jakobsen B.K. Making high-affinity T-cell receptors: a new class of targeted therapeutics. IDrugs 2006, 9:554-559.
28. Bowerman N.A., Crofts T.S., Chlewicki L., Do P., Baker B.M., Christopher Garcia K., Kranz D.M. Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity. Mol Immunol 2009, 46:3000-3008.
29. Garcia K.C., Adams J.J., Feng D., Ely L.K. The molecular basis of TCR germline bias for MHC is surprisingly simple. Nat Immunol 2009, 10:143-147.
30. Rudolph M.G., Stanfield R.L., Wilson I.A. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006, 24:419-466.
31. Borbulevych O.Y., Santhanagopolan S.M., Hossain M., Baker B.M. TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms. J Immunol 2011, 187:2453-2463.
32. Cole D.K., Yuan F., Rizkallah P.J., Miles J.J., Gostick E., Price D.A., Gao G.F., Jakobsen B.K., Sewell A.K. Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem 2009, 284:27281-27289.
33. Garboczi D.N., Ghosh P., Utz U., Fan Q.R., Biddison W.E., Wiley D.C. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996, 384:134-141.
34. Morgan R.A., Chinnasamy N., Abate-Daga D., Gros A., Robbins P.F., Zheng Z., Dudley M.E., Feldman S.A., Yang J.C., Sherry R.M., et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013, 36:133-151.
35. Marrack P., Scott-Browne J.P., Dai S., Gapin L., Kappler J.W. Evolutionarily conserved amino acids that control TCR-MHC interaction. Annu Rev Immunol 2008, 26:171-203.
36. Chervin A.S., Stone J.D., Soto C.M., Engels B., Schreiber H., Roy E.J., Kranz D.M. Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses. Gene Ther 2013, 20:634-644.
37. Smith S.N., Sommermeyer D., Piepenbrink K.H., Blevins S.J., Bernhard H., Uckert W., Baker B.M., Kranz D.M. Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes. J Mol Biol 2013, 425:4496-4507.
38. Irvine D.J., Purbhoo M.A., Krogsgaard M., Davis M.M. Direct observation of ligand recognition by T cells. Nature 2002, 419:845-849.
39. Purbhoo M.A., Irvine D.J., Huppa J.B., Davis M.M. T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol 2004, 5:524-530.
40. Sykulev Y., Joo M., Vturina I., Tsomides T.J., Eisen H.N. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 1996, 4:565-571.
41. Vitiello A., Marchesini D., Furze J., Sherman L.A., Chesnut R.W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 1991, 173:1007-1015.
42. Newberg M.H., Smith D.H., Haertel S.B., Vining D.R., Lacy E., Engelhard V.H. Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J Immunol 1996, 156:2473-2480.
43. Zhong S., Malecek K., Johnson L.A., Yu Z., Vega-Saenz de Miera E., Darvishian F., McGary K., Huang K., Boyer J., Corse E., et al. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc Natl Acad Sci U S A 2013, 110:6973-6978.
44. Colella T.A., Bullock T.N., Russell L.B., Mullins D.W., Overwijk W.W., Luckey C.J., Pierce R.A., Restifo N.P., Engelhard V.H. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med 2000, 191:1221-1232.
45. Mullins D.W., Bullock T.N., Colella T.A., Robila V.V., Engelhard V.H. Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice. J Immunol 2001, 167:4853-4860.
46. Gregg R.K., Nichols L., Chen Y., Lu B., Engelhard V.H. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J Immunol 2010, 184:1909-1917.
47. Nichols L.A., Chen Y., Colella T.A., Bennett C.L., Clausen B.E., Engelhard V.H. Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J Immunol 2007, 179:993-1003.
48. Schmitt T.M., Aggen D.H., Stromnes I.M., Dossett M.L., Richman S.A., Kranz D.M., Greenberg P.D. Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood 2013, 122:348-356.
49. Inoue K., Ogawa H., Sonoda Y., Kimura T., Sakabe H., Oka Y., Miyake S., Tamaki H., Oji Y., Yamagami T., et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997, 89:1405-1412.
50. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 1998, 19:395-404.
51. Petrova G., Ferrante A., Gorski J. Cross-reactivity of T cells and its role in the immune system. Crit Rev Immunol 2012, 32:349-372.
52. Jones L.L., Colf L.A., Stone J.D., Garcia K.C., Kranz D.M. Distinct CDR3 conformations in TCRs determine the level of cross-reactivity for diverse antigens, but not the docking orientation. J Immunol 2008, 181:6255-6264.
53. Holler P.D., Kranz D.M. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 2003, 18:255-264.
54. Cameron B.J., Gerry A.B., Dukes J., Harper J.V., Kannan V., Bianchi F.C., Grand F., Brewer J.E., Gupta M., Plesa G., et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 2013, 5:197ra103.
55. Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., Staehler M., Brugger W., Dietrich P.Y., Mendrzyk R., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012, 18:1254-1261.
56. Engels B., Engelhard V.H., Sidney J., Sette A., Binder D.C., Liu R.B., Kranz D.M., Meredith S.C., Rowley D.A., Schreiber H. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 2013, 23:516-526.
57. Matsushita H., Vesely M.D., Koboldt D.C., Rickert C.G., Uppaluri R., Magrini V.J., Arthur C.D., White J.M., Chen Y.S., Shea L.K., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400-404.
58. Tran E., Turcotte S., Gros A., Robbins P.F., Lu Y.C., Dudley M.E., Wunderlich J.R., Somerville R.P., Hogan K., Hinrichs C.S., et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014, 344:641-645.
59. Weinschenk T., Gouttefangeas C., Schirle M., Obermayr F., Walter S., Schoor O., Kurek R., Loeser W., Bichler K.H., Wernet D., et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002, 62:5818-5827.